Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Rating) CEO John L. Higgins sold 2,000 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $90.00, for a total transaction of $180,000.00. Following the completion of the sale, the chief executive officer now directly owns 367,180 shares of the company’s stock, valued at approximately $33,046,200. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Ligand Pharmaceuticals Stock Performance
LGND opened at $87.85 on Friday. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $72.57 and a fifty-two week high of $169.98. The firm’s fifty day moving average is $96.40 and its 200 day moving average is $95.71. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -190.98, a price-to-earnings-growth ratio of 4.55 and a beta of 1.10.
Wall Street Analyst Weigh In
A number of research firms have commented on LGND. BMO Capital Markets began coverage on shares of Ligand Pharmaceuticals in a research report on Thursday, June 16th. They issued an “outperform” rating for the company. StockNews.com raised shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 10th. Barclays cut their price objective on shares of Ligand Pharmaceuticals from $165.00 to $157.00 and set an “overweight” rating for the company in a research report on Tuesday, July 5th. Finally, Roth Capital cut their price objective on shares of Ligand Pharmaceuticals from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Friday, September 2nd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $177.00.
Institutional Inflows and Outflows
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
- Get a free copy of the StockNews.com research report on Ligand Pharmaceuticals (LGND)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It’s a Down Week
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.